Login | Register

Pfizer Gets A NO From EMA On Taliglucerase Alfa For Gaucher Disease

The European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP), has recommended against issuing marketing authorization for Taliglucerase Alfa, an enzyme replacement treatment for Gaucher disease. Gaucher disease is estimated to affect some 1 in 50,000 to 1 in 100,000 people in the general population...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *